DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--US Introduction of FORUM Glaucoma Workplace from ZEISS
ZEISS announces the US release of a new glaucoma diagnostic and management software application, FORUM® Glaucoma Workplace. FORUM Glaucoma Workplace, an application available in the FORUM data management system, supports efficient clinical assessment at the point of care by delivering exam data in new clinically relevant ways.
“With FORUM and the new FORUM Glaucoma Workplace, ZEISS provides doctors with an integrated solution that allows them to see glaucoma in a completely different light -- by bringing together in new ways the structural and functional data and analyses from gold standard diagnostic devices,” says Dr. Ludwin Monz, President and CEO, Carl Zeiss Meditec AG.
FORUM Glaucoma Workplace provides off-instrument review of data from the Humphrey® Field Analyzer (HFA™) in the exam lane, and virtually anywhere in the practice. The application also enables interactive functional Guided Progression Analysis™ (GPA™) to help identify patients who are progressing and at risk for further visual field loss. With interactive GPA, doctors can adjust GPA parameters as needed, change baselines, reset baselines after surgery, or exclude outliers.
Through FORUM, clinicians have immediate access to visual field data, OCT scans, and fundus images to support their glaucoma diagnosis and management. The HFA-CIRRUS Combined Report simplifies interpretation and provides at-a-glance assessment of structural and functional data.
Comprehensive clinical applications and analyses for glaucoma through the gold standard CIRRUS OCT and HFA from ZEISS
CIRRUS™ OCT offers advanced clinical applications for the diagnosis and management of glaucoma and retinal diseases. Structural analyses are rapidly configured from the densely layered exam data of the CIRRUS SmartCube, exclusive to ZEISS, into informative maps, metrics and visualizations to aid doctors in their clinical assessments. The CIRRUS SmartCube enables anatomy-based Optic Nerve Head Assessment, first introduced by ZEISS in 2010, which accounts for complex disc morphology, including titled discs, atrophy, and other challenging pathologies. The SmartCube also enables doctors to confidently assess their patient’s glaucoma status with Ganglion Cell and RNFL Assessments and with structural GPA indicating statistically significant change over time to the RNFL and ONH. AutoCenter™ heightens the clinical efficiency and consistency by automatically placing the ONH and RNFL analyses on the disc.
The Gold Standard HFA analyzes visual fields and provides functional GPA and the Visual Field Index™ (VFI™), a simple and intuitive global index that illustrates trend over time to project future vision loss. Additionally, the HFA provides a GPA alert which indicates statistically significant deterioration over consecutive exams.
“With FORUM Glaucoma Workplace, ZEISS has truly created something exceptional. FORUM enables me to view structure and function together using dynamic and malleable data. Not only does it enhance my clinical capabilities, it expands them,” says Steven D. Vold, MD, President and Medical Director, Vold Vision.
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2011/12 (ended 30 September) the company's around 2,400 employees generated revenue of just under EUR 862 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65% are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.
For more information, please go to: www.meditec.zeiss.com
